Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global
innovator in drug-delivery platforms, recently launched its ChrgD+ product, a
water-soluble, multispectrum hemp oil in a powdered format powered by the
company’s proprietary DehydraTECH(TM) technology for rapid CBD delivery (http://ibn.fm/Ljt7D). An article
discussing the company reads, “The rapid biodelivery of CBD through DehydraTECH
provides an avenue for safer, less-conspicuous consumption of CBD than inhaling
it through smoke or vapor during a critical time when social acceptance of
cannabis products is exploding age-old prohibitions but many legislative
entities continue to struggle with regulatory issues on behalf of the public
welfare. . . . ChrgD+ has been available in a limited number of retail stores
throughout the Western United States, but the announcement that it is now
available via commercial web delivery to locations where it can be legally
consumed means that anyone has the potential to obtain it through the website www.ChrgD.life without
having to travel. Limited-time promotional offers and product updates are also
available through the site.”
To view the full article, visit http://ibn.fm/8mNmZ
About Lexaria Bioscience Corp.
Lexaria is a global innovator in drug-delivery platforms.
Its patented DehydraTECH drug-delivery technology changes the way active
pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion
methods, lower overall dosing and higher effectiveness for lipophilic active
molecules. DehydraTECH increases bio-absorption, reduces time of onset, and
masks unwanted tastes for orally administered bioactive molecules including
cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine
and other molecules. Lexaria has licensed DehydraTECH to multiple companies in
the cannabis industry for use in cannabinoid beverages, edibles and oral
products, as well as to a world-leading tobacco producer for the development of
smokeless, oral-based nicotine products. Lexaria operates a licensed in-house
research laboratory and holds a robust intellectual property portfolio with 16
patents granted and more than 60 patents pending worldwide. For more
information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
